A bifunctional dihydrofolate synthetase–folylpolyglutamate synthetase in Plasmodium falciparum identified by functional complementation in yeast and bacteria
详细信息 查看全文
- 作者：Salcedo ; Enrique ; Cortese ; Joseph F. ; Plowe ; Christopher V. ; Sims ; Paul F.G. ; Hyde ; John E.
- 关键词：Antifolate drugs ; Bifunctional gene ; E. coli ; Folate biosynthesis ; Heterologous expression ; Saccharomyces cerevisiae ; DHFR (dhfr) ; dihydrofolate reductase (gene) ; DHFS (dhfs) ; dihydrofolate synthetase (gene) ; DHPS (dhps) ; dihydropteroate synthetase (gene)
- 刊名：Molecular and Biochemical Parasitology
- 出版年：2001
- 出版时间：February, 2001
- 年：2001
- 卷：112
- 期：2
- 页码：239-252
- 全文大小：645 K
文摘
Folate metabolism in the human malaria parasite Plasmodium falciparum is an essential activity for cell growth and replication, and the target of an important class of therapeutic agents in widespread use. However, resistance to antifolate drugs is a major health problem in the developing world. To date, only two activities in this complex pathway have been targeted by antimalarials. To more fully understand the mechanisms of antifolate resistance and to identify promising targets for new chemotherapies, we have cloned genes encoding as yet uncharacterised enzymes in this pathway. By means of complementation experiments using 1-carbon metabolism mutants of both Escherichia coli and Saccharomyces cerevisiae, we demonstrate here that one of these parasite genes encodes both dihydrofolate synthetase (DHFS) and folylpolyglutamate synthetase (FPGS) activities, which catalyse the synthesis and polyglutamation of folate derivatives, respectively. The malaria parasite is the first known example of a eukaryote encoding both DHFS and FPGS activities in a single gene. DNA sequencing of this gene in antifolate-resistant strains of P. falciparum, as well as drug-inhibition assays performed on yeast and bacteria expressing PfDHFS–FPGS, indicate that current antifolate regimes do not target this enzyme. As PfDHFS–FPGS harbours two activities critical to folate metabolism, one of which has no human counterpart, this gene product offers a novel chemotherapeutic target with the potential to deliver a powerful blockage to parasite growth.